CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I, Multicenter, Open-Label, Dose-escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Orally Administered LP-168 in Subjects With Relapsed or Refractory B-cell Malignancies.

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04775745
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:25.959902+00:00
Published At: 2026-02-13T00:00:00+00:00
Record Updated At: 2026-02-13
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["CLL/SLL", "Waldenstrom Macroglobulinemia", "Follicular Lymphoma", "Diffuse Large B Cell Lymphoma", "Mantle Cell Lymphoma", "Marginal Zone Lymphoma", "Hairy Cell Leukemia"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-02-13"
protocolSection.identificationModule.nctId: "NCT04775745"
protocolSection.identificationModule.officialTitle: "A Phase I, Multicenter, Open-Label, Dose-escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Orally Administered LP-168 in Subjects With Relapsed or Refractory B-cell Malignancies."
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.